Key Points
- Insider selling: Francis Lo sold 4,394 shares on Dec. 22 at $17.50 for $76,895 and had earlier sold 113,890 shares on Dec. 15 at $15.57 (~$1.77M), trimming his stake by 1.37% and leaving him with 315,978 shares (~$5.53M).
- Fundamentals and outlook: Adaptive beat revenue estimates with $93.97M (vs. $58.76M est.), up 102.4% YoY and posted a slight EPS beat (‑$0.15 vs. ‑$0.16), while analysts' consensus is a "Moderate Buy" with an average target of $17.11.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Francis Lo sold 4,394 shares of the business's stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00. Following the completion of the sale, the insider directly owned 315,978 shares in the company, valued at $5,529,615. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Francis Lo also recently made the following trade(s):
- On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30.
Adaptive Biotechnologies Stock Performance
Adaptive Biotechnologies stock opened at $16.65 on Tuesday. The company has a market capitalization of $2.54 billion, a PE ratio of -30.83 and a beta of 2.20. Adaptive Biotechnologies Corporation has a fifty-two week low of $5.91 and a fifty-two week high of $20.76. The firm has a 50 day moving average price of $16.60 and a 200 day moving average price of $13.97.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $93.97 million during the quarter, compared to analyst estimates of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The company's quarterly revenue was up 102.4% on a year-over-year basis. During the same period last year, the business posted ($0.22) earnings per share. As a group, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ADPT has been the topic of a number of recent research reports. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 30th. They set a "buy" rating and a $20.00 price target on the stock. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an "equal weight" rating and a $21.00 price objective for the company. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an "overweight" rating in a report on Thursday, November 6th. Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of "Moderate Buy" and an average price target of $17.11.
Get Our Latest Stock Report on Adaptive Biotechnologies
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Braidwell LP purchased a new stake in shares of Adaptive Biotechnologies in the 1st quarter valued at approximately $35,692,000. Ameriprise Financial Inc. increased its holdings in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company's stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company's stock valued at $36,523,000 after buying an additional 2,062,282 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Adaptive Biotechnologies in the third quarter valued at $14,934,000. Finally, First Trust Advisors LP lifted its holdings in Adaptive Biotechnologies by 4,802.2% during the 2nd quarter. First Trust Advisors LP now owns 741,306 shares of the company's stock worth $8,636,000 after buying an additional 726,184 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
